» Articles » PMID: 33617511

A Critical Appraisal of Evidence- and Consensus-Based Guidelines for Actinic Keratosis

Overview
Journal Curr Oncol
Publisher MDPI
Specialty Oncology
Date 2021 Feb 22
PMID 33617511
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Actinic keratoses (AK) are common lesions of the skin that can be effectively treated with several lesion- and field-directed treatments. Clinical practice guidelines assist physicians in choosing the appropriate treatment options for their patients. Here, we aimed to systematically identify and evaluate the methodological quality of currently available guidelines for AK. Guidelines published within the last 5 years were identified in a systematic search of guideline databases, Medline and Embase. Then, six independent reviewers evaluated the methodological quality using the tools "Appraisal of Guidelines for Research and Evaluation" (AGREE II) and "Recommendation EXcellence" (AGREE-REX). The Kruskal-Wallis (H) test was used to explore differences among subgroups and Spearman's correlation to examine the relationship between individual domains. Three guidelines developed by consortia from Canada, Germany and the United Kingdom were eligible for the evaluation. The German guideline achieved the highest scores, fulfilling 65 to 92% of the criteria in AGREE II and 67 to 84% in AGREE-REX, whereas the Canadian guideline scored 31 to 71% of the criteria in AGREE II and 33 to 46% in AGREE-REX. The domains "stakeholder involvement" and "values and preferences" were identified as methodological weaknesses requiring particular attention and improvement in future guideline efforts.

Citing Articles

Systematic evaluation of Merkel cell carcinoma clinical practice guidelines using the AGREE II instrument.

Lakshmipathy D, Fritz C, Harris J, Athni T, Go B, Moreira A Arch Dermatol Res. 2024; 316(5):130.

PMID: 38662106 PMC: 11045602. DOI: 10.1007/s00403-024-02853-0.


Medical gas plasma technology: Roadmap on cancer treatment and immunotherapy.

Bekeschus S Redox Biol. 2023; 65:102798.

PMID: 37556976 PMC: 10433236. DOI: 10.1016/j.redox.2023.102798.

References
1.
Steeb T, Wessely A, von Bubnoff D, Dirschka T, Drexler K, Falkenberg C . Treatment Motivations and Expectations in Patients with Actinic Keratosis: A German-Wide Multicenter, Cross-Sectional Trial. J Clin Med. 2020; 9(5). PMC: 7290787. DOI: 10.3390/jcm9051438. View

2.
Nast A, Spuls P, Ormerod A, Reytan N, Saiag P, Smith C . A critical appraisal of evidence-based guidelines for the treatment of psoriasis vulgaris: 'AGREE-ing' on a common base for European evidence-based psoriasis treatment guidelines. J Eur Acad Dermatol Venereol. 2009; 23(7):782-7. DOI: 10.1111/j.1468-3083.2009.03166.x. View

3.
Criscione V, Weinstock M, Naylor M, Luque C, Eide M, Bingham S . Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer. 2009; 115(11):2523-30. DOI: 10.1002/cncr.24284. View

4.
Brouwers M, Kho M, Browman G, Burgers J, Cluzeau F, Feder G . AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ. 2010; 182(18):E839-42. PMC: 3001530. DOI: 10.1503/cmaj.090449. View

5.
Steeb T, Wessely A, Leiter U, French L, Berking C, Heppt M . The more the better? An appraisal of combination therapies for actinic keratosis. J Eur Acad Dermatol Venereol. 2019; 34(4):727-732. DOI: 10.1111/jdv.15998. View